Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study (Q31918177)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study |
scientific article |
Statements
1 reference
Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study (English)
1 reference
K Henry
1 reference
R J Wallace
1 reference
P C Bellman
1 reference
D Norris
1 reference
R L Fisher
1 reference
L L Ross
1 reference
Q Liao
1 reference
M S Shaefer
1 reference
TARGET Study Team
1 reference
11 January 2001
1 reference
1 reference
183
1 reference
571-578
1 reference
Identifiers
1 reference
1 reference